the market could not stop it because there is a securities trading agreement for a total of sessions with Lanstead.
the hypothesis of acquisition from anyone that can come is what is trying to avoid the company; the market declines the capitalization in order to have more aggressiveness, but those of Neuren to numbers in hand, with the conversion of options to managers are safe and armored then, or receive a fabulous offer or contunuano to pursue their project that finally is moved to NNZ-2591. all the events of the last year including the more or less explicit contents of the company's announcements to the market, indicate a clear position in the advance 2591. Basically Trofinetide for Rett is now assigned to the biotech that has not required anything in more for the moment while everything must happen around 2591, so my best invitation is to go further and start thinking seriously about the future of Neuren in terms of development and what goes behind NNZ-2591.
the starting point that is not so so is contained in the company release perfectly 4 years ago or in August 2014; reading, one realizes how current the press is and how much forward and how Trofinetide interfaces with what the company is doing right in this period; NNZ-2591 is perfectly set up to adopt all the scientific knowledge and progress achieved with Trofinetide, so be careful that we are ahead of what we want to believe in devaluing our capitalization.
I also invite you to carefully read what David Clarke declared today 12 years ago, responsible for the Pifzer experimentation on 2591, and how it was already positioned at the time. I firmly believe that this is the main turning point in the short and of great value for the future and on which we need to focus our attention and reasoning immediately.
https://stocknessmonster.com/announcements/neu.asx-2A810967/
http://www.scoop.co.nz/stories/BU0608/S00050/new-compound-targeted-for-treatment-of-parkinsons.htm
https://www.researchgate.net/profile/David_Clarke37
the market could not stop it because there is a securities...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.61 |
Change
-0.590(4.15%) |
Mkt cap ! $1.739B | |||
| Open | High | Low | Value | Volume |
| $13.88 | $13.91 | $13.29 | $13.29M | 982.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $13.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.63 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |